Aardvark Therapeutics (AARD) Operating Leases (2024 - 2026)

Aardvark Therapeutics (AARD) posted Operating Leases of $116000.0 for Q3 2025, down 49.12% sequentially from $228000.0 in Q2 2025.

Aardvark Therapeutics (AARD) Operating Leases (2024 - 2026) Analysis & Trends

Aardvark Therapeutics has reported Operating Leases for 2 years, with the latest figure at $116000.0 in Q3 2025.

Quarterly Operating Leases changed N/A year-over-year to $116000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $116000.0 (changed N/A YoY) and the FY2024 annual result came in at $441000.0, changed N/A from the prior year.
Operating Leases retreated to $116000.0 in Q3 2025 per AARD's latest filing, from $228000.0 in the prior quarter.
Over five years, Operating Leases peaked at $441000.0 in Q4 2024 and troughed at $116000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Aardvark Therapeutics	127.36 Mn	53.44 Mn	-

Download Data